Novo Nordisk Secures FDA Approval for Awiqli®, First Once-Weekly Basal Insulin for Type 2 Diabetes

summarizeSummary

Novo Nordisk announced FDA approval for Awiqli® (insulin icodec-abae), the first and only once-weekly basal insulin for adults with type 2 diabetes, with a US launch anticipated in the second half of 2026.

check_boxKey Events

• FDA Approval for Awiqli®

  The US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL for adults with type 2 diabetes.

• First Once-Weekly Basal Insulin

  Awiqli® is the first and only once-weekly, long-acting basal insulin approved by the FDA, offering a significant convenience advantage over daily injections.

• US Launch Expected H2 2026

  Novo Nordisk anticipates launching Awiqli® nationwide in the US in the second half of 2026.

• Strong Clinical Efficacy

  The approval is supported by the ONWARDS phase 3a program, which demonstrated efficacy in HbA1c reduction consistent with the daily basal insulin class, with a similar safety profile.

auto_awesomeAnalysis

This FDA approval for Awiqli® marks a significant milestone for Novo Nordisk, introducing the first and only once-weekly basal insulin for adults with type 2 diabetes. This innovation could substantially improve patient adherence and quality of life by reducing daily injections to a single weekly dose, potentially capturing significant market share in the competitive diabetes treatment landscape. The approval strengthens Novo Nordisk's leading position in diabetes care and provides a strong positive catalyst, especially as the stock is currently trading near its 52-week low. The planned US launch in the second half of 2026 positions the company for future revenue growth.